Pang Qianyun, Liu Hongliang, Chen Bo, Jiang Yan
Department of Anesthesia, Chongqing Cancer Institute/ Hospital/Cancer Center, Chongqing, China. E-mail.
Saudi Med J. 2017 Feb;38(2):123-131. doi: 10.15537/smj.2017.2.15077.
To determine whether perioperative fluid restrictive administration can reduce specific postoperative complications in adults undergoing major abdominal surgery. Methods: We searched the MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials, Google scholar, and article reference lists (up to December 2015) for studies that assessed fluid therapy and morbidity or mortality in patients undergoing major abdominal surgeries. The quality of the trials was assessed using the Jadad scoring system, and a meta-analysis of the included randomized, controlled trials was conducted using Review Manager software, version 5.2. Results: Ten studies with a total of 1160 patients undergoing major abdominal surgeries were included. We found that perioperative restrictive fluid therapy could reduce the risk of postoperative infectious complications (odds ratio [OR]=0.54, 95% confidence interval [CI]: 0.39-0.74, p=0.0001, I2=37%), pulmonary complications (OR=0.49, 95% CI: 0.26-0.93, p=0.03, I2=50%), and cardiac complications (OR=0.45, 95% CI: 0.29-0.69, p=0.0003, I2=48%), but had no effect on the risk of gastrointestinal complications (OR=0.87, 95% CI: 0.51-1.46, p=0.59, I2=0%), renal complications (OR=0.76, 95% CI: 0.43-1.34, p=0.35, I2=0%), and postoperative mortality (OR=0.62, 95% CI: 0.25-1.50, p=0.29, I2=0%). Conclusion: Perioperative restrictive fluid administration was superior to liberal fluid administration in reducing the infectious, pulmonary and cardiac complications after major abdominal surgeries.
确定围手术期限制性液体管理能否减少接受大型腹部手术的成人患者特定的术后并发症。方法:我们检索了MEDLINE、EMBASE和Cochrane对照试验中心注册库、谷歌学术以及文章参考文献列表(截至2015年12月),以查找评估大型腹部手术患者液体治疗及发病率或死亡率的研究。使用Jadad评分系统评估试验质量,并使用Review Manager 5.2版软件对纳入的随机对照试验进行荟萃分析。结果:纳入了10项研究,共1160例接受大型腹部手术的患者。我们发现围手术期限制性液体治疗可降低术后感染性并发症风险(比值比[OR]=0.54,95%置信区间[CI]:0.39 - 0.74,p = 0.0001,I² = 37%)、肺部并发症风险(OR = 0.49,95% CI:0.26 - 0.93,p = 0.03,I² = 50%)和心脏并发症风险(OR = 0.45,95% CI:0.29 - 0.69,p = 0.0003,I² = 48%),但对胃肠道并发症风险(OR = 0.87,95% CI:0.51 - 1.46,p = 0.59,I² = 0%)、肾脏并发症风险(OR = 0.76,95% CI:0.43 - 1.34,p = 0.35,I² = 0%)和术后死亡率(OR = 0.62,95% CI:0.25 - 1.50,p = 0.29,I² = 0%)无影响。结论:围手术期限制性液体管理在降低大型腹部手术后的感染性、肺部和心脏并发症方面优于自由液体管理。